Feedback / Questions
AIC100 - AffyImmune Therap
https://www.businesswire.com/news/home/20240723305679/en/AffyImmune-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-AIC100-in-Recurrent-Anaplastic-Thyroid-Cancer
Jul 23, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next